Revolution Medicines, Inc. (RVMD)
NMS – Real vaqt narxi. Valyuta: USD
92.51
-0.70 (-0.75%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
91.05
-1.46 (-1.58%)
Bozordan keyin: Mar 27, 2026, 7:33 PM EDT

NMS – Real vaqt narxi. Valyuta: USD
92.51
-0.70 (-0.75%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
91.05
-1.46 (-1.58%)
Bozordan keyin: Mar 27, 2026, 7:33 PM EDT
Revolution Medicines, Inc., klinik tadqiqot bosqichidagi aniq onkologiya kompaniyasi RASga bog'liq bo'lgan saraton turlari uchun yangi maqsadli terapiyalarni ishlab chiqadi. Kompaniyaning tadqiqot va ishlanmalar portfelida RAS(ON) inhibitörlari mavjud bo'lib, ular RAS variantlariga bog'lanadi va boshqa RAS(ON) inhibitörlari bilan birgalikda yoki RAS hamroh inhibitorlari yoki boshqa terapevtik vositalar bilan birgalikda monoterapiya sifatida ishlatiladi, shuningdek, RASga bog'liq bo'lgan saratonni qo'llab-quvvatlovchi hamkorlikdagi maqsadlar va yo'llarni bostirish uchun RAS hamroh inhibitorlari mavjud. Uning RAS(ON) inhibitörlari orasida daraksonrasib (RMC-6236), qattiq o'smalarni davolash uchun dastlabki klinik rivojlanishda bo'lgan elironrasib G12C (RMC-6291) va 1L PDAC bemorlarida daraksonrasib va zoldonrasib kombinatsiyasini baholayotgan 3-bosqichli ro'yxatga olish tadqiqotida bo'lgan zoldonrasib G12D (RMC-9805) mavjud; va ishlanmalar nomzodlari orasida klinik tadqiqotda bo'lgan RMC-5127 (G12V), klinik tadqiqotda bo'lgan RMC-0708 (Q61H) va RMC-8839 (G13C) kiradi. Revolution Medicines, Inc. 2014 yilda tashkil etilgan va Redwood City, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Mark A. Goldsmith M.D., Ph.D. | CEO, President & Chairman |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development |
| Mr. Jack Anders | Chief Financial Officer |
| Mr. Walter Reiher Ph.D. | Chief Information Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2025-11-05 | 10-Q | rvmd-20250930.htm |
| 2025-10-17 | 8-K | d32252d8k.htm |
| 2025-09-10 | 8-K | d947102d8k.htm |
| 2025-08-06 | 8-K | rvmd-20250806.htm |
| 2025-06-27 | 8-K | d12458d8k.htm |
| 2025-06-24 | 8-K | d838043d8k.htm |
| 2025-06-18 | 8-K | d935264d8k.htm |
| 2025-05-07 | 10-Q | rvmd-20250331.htm |
| 2025-04-29 | ARS | d933799dars.pdf |
| 2025-02-26 | 10-K | rvmd-20241231.htm |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer |
| Ms. Xiaolin Wang | Executive Vice President of Development |